Raymond James analyst Danielle Brill says the news that the European Medicines Agency’s CHMP reversed course and issued a positive recommendation for the marketing authorization of Leqembi in the EU for early Alzheimer’s “comes at a surprise to us,” but the expanding marketing authorization the the EU doesn’t change the firm’s “overarching view” that the launch is unlikely to achieve the level of success that investors had originally hoped for. With a narrow label, the firm believes uptake in the EU will be “(even) more modest than what we’ve seen in the U.S.,” adds the analyst, who reiterates a Market Perform rating on Biogen (BIIB) shares.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Eisai receives positive CHMP opinion for Lecanemab in early Alzheimer’s disease
- EMA recommends Leqembi for treatment of early Alzheimer’s disease
- Biogen up 5% after EMA recommends Leqembi for early Alzheimer’s disease
- American upgraded, Regeneron initiated: Wall Street’s top analyst calls
- Biogen initiated with a Neutral at Citi